Genkyotex SA’s Setanaxib (GKT 831) is a small molecule NOX inhibitor currently in Phase III clinical trials and a potential treatment solution for Primary Biliary Cholangitis (PBC). PBC is a chronic and progressive condition characterized by the inflammation and subsequent destruction of the small bile ducts within the liver. Setanaxib is a novel selective inhibitor of NADPH oxidase (NOX) 1 and 4 isoforms, enabling the downregulation of multiple fibrogenic and inflammatory pathways to prevent progression of liver fibrosis. The mechanism of action of setanaxib involves both anti-fibrotic and anti-inflammatory effects.